US20040142036A1 - Metering and packaging of controlled release medication - Google Patents
Metering and packaging of controlled release medication Download PDFInfo
- Publication number
- US20040142036A1 US20040142036A1 US10/756,124 US75612404A US2004142036A1 US 20040142036 A1 US20040142036 A1 US 20040142036A1 US 75612404 A US75612404 A US 75612404A US 2004142036 A1 US2004142036 A1 US 2004142036A1
- Authority
- US
- United States
- Prior art keywords
- delivery package
- pharmaceutical delivery
- mixture
- pharmaceutical
- package according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C[C@@]1C(C2)=C2C*1 Chemical compound C[C@@]1C(C2)=C2C*1 0.000 description 4
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Definitions
- the present invention relates to the packaging of dry powders and particularly to the metering and packaging of precise quantities of pharmaceuticals and drugs for medical uses.
- the invention has particular utility in the metering and packaging of dry powders, particularly precise amounts of dry powder pharmaceuticals and drugs, and will be described in connection with such utility, although other utilities are contemplated.
- controlled-release is used to describe a system, i.e. method and materials for making an active ingredient available to the patient in accordance with a preselected condition, i.e. time, site, etc
- Controlled-release includes the use of instantaneous release, delayed release and sustained release.
- Instantaneous release refers to immediate release to the patient.
- Dellayed release means the active ingredient is not made available until some time delay after administration. Typically, dosages are administered by oral ingestion, although other forms of administration are contemplated in accordance with the present invention.
- sustained release refers to release of active ingredient whereby the level of active ingredient available to the patient is maintained at some level over a period of time. The method of effecting each type of release can be varied. For example, the active-ingredient can be placed on a semi-permeable membrane having predetermined diffusion, dissolution, erosion or breakdown characteristics.
- the active ingredient can be masked by a coating, a laminate, etc.
- the present invention contemplates delivery of a controlled-release system which utilizes one or more of the “release” methods and materials.
- the present invention advantageously can be employed in the development of multiple different release system(s).
- SR systems focus on the fabrication of laminates of polymeric material and therapeutic agent which are then formed into a sandwich, relying on different diffusion or erosion rates to control release of the therapeutic agent.
- Liquid-liquid encapsulation in a viscous syrup-like solution of polymer also has been known to be useful in controlling release of the therapeutic agent.
- heterogeneous dispersions or solutions of therapeutic agents in water-swellable hydrogen matrices are useful in controlling the release of the agent by slow surface-to-center swelling of the matrix and subsequent diffusion of the agent from the water-swollen part of the matrix.
- the dosage form During dissolution of a controlled-release matrix tablet, the dosage form generally remains as a non-disintegrating, slowly eroding entity from which the therapeutic agent leaches out, through a diffusion controlled process.
- Conventional SR formulations are generally designed to release their active ingredients over an extended period of time, usually 8-24 hours.
- Conventional SR formulations use waxes or hydrophilic gums as the primary drug carriers to prolong the release of the active ingredients.
- Starch USP (potato or corn) is commonly used as a component in conventional tablet or hard shell capsule formulations.
- the existing sustained release technologies generally involve relatively complicated formulations and manufacturing processes which often are difficult and expensive to precisely control.
- OROS SR delivery system
- OROS SR delivery system
- the dosage unit should be able to deliver the system without interfering with its release pattern.
- controlled-release systems have been provided in the form of beads or particles which are packaged in a gelatin capsule for oral dosage. This method of delivery of the controlled-release system prevents damage to the coating on the beads.
- Electrostatic charge has been employed to attract a given quantity of powder to a surface.
- An example of this is the laser printer or the electrostatic copy device where a drum is charged and toner particles are attracted and held in position by the charge. The charge on the drum is neutralized by the attracted toner powder, thus limiting the amount of toner in accordance with the charge image on the drum. The charged powder on the printer drum is then transferred to a sheet of paper or other carrier to give a final image.
- electrostatic charge technology is employed for transferring a predetermined amount of a finely powdered pharmaceutical or drug to a carrier or an intermediate such as a drum, carrying a charge of predetermined intensity and area, rotating the charged drum surface, carrying the predetermined amount of powdered pharmaceutical or drug on its surface, to a transfer station where the charge is overcome and the dry powder is transferred to a package which is then sealed.
- a drum a belt, or other movable surface is charged to a given potential in a localized area.
- a predetermined amount of powdered pharmaceutical or drug may be deposited directly in a package using electrostatic charge technology.
- the charge and area of charge can be determined experimentally for each dose of pharmaceutical or drug and each particle size distribution. This can be done by controlling either the charged area for a given charge density or the total electrostatic charge on any individual charged area. These conditions can be adjusted to provide essentially the exact desired amount of the particular pharmaceutical or drug to be transferred at the transfer station.
- controlled quantities of powdered medication are formed in controlled release packages using electrostatic metering technology.
- the present invention also provides, in another aspect, combination medication delivery systems in which the active ingredients are segregated from one another
- FIG. 1 is a schematic flow diagram showing the various steps involved in practicing the present invention
- FIG. 2 is an enlarged cross-sectional view of one embodiment of a controlled release tablet made in accordance with the present invention
- FIG. 3 is a view, similar to FIG. 1, and showing alternative steps involved in practicing the present invention
- FIG. 4 is a view, similar to FIG. 2, and showing an alternative form of a controlled release tablet made in accordance with the present invention
- FIG. 5 is a view similar to FIG. 2, and showing yet another alternative embodiment of the present invention.
- FIG. 6 is a view, similar to FIG. 2, and showing yet another embodiment of the invention.
- FIGS. 7 - 9 are views similar to FIG. 2, and showing yet other embodiments of the present invention.
- FIG. 1 there is a schematic flow diagram of the various pieces of equipment needed to perform in the total process from powder supply to packaged pharmaceutical or drug, i.e. in controlled release tablet form, containing a specified amount of pharmaceutical or drug powder in the tablet or package.
- the pharmaceutical or drug powder supply which is fed into a device 18 for creating an aerosol of the powder.
- the powder particles are ionized at 20 .
- a carrier surface capable of maintaining a space charge on its surface. This can be a plastic belt, for example, or a selenium drum of the type used in XeroxTM photocopiers.
- This carrier surface 24 is passed through a charging station 25 where a predetermined electrostatic charge 25 A (an electrostatic “image”) is created on a predetermined area of the transfer surface.
- This charged surface 25 A then passes through a step 26 wherein powder is deposited on the carrier surface in a sufficient amount 26 A to neutralize the charge carried by the carrier surface.
- the carrier surface, carrying the predetermined amount 26 A of powder on its surface is passed to a powder discharging device 30 which discharges the powder 26 A from the surface 24 onto a membrane 29 .
- the powder may be placed directly onto the membrane 29 .
- the membrane 29 containing its charge of powder 26 A then passes through a sealing step 32 wherein a second membrane 34 which may be porous, permeable or semi-permeable covers and seals the discharged powder 26 A on the membrane 29 .
- a second membrane 34 which may be porous, permeable or semi-permeable covers and seals the discharged powder 26 A on the membrane 29 .
- This sandwiched material is then passed to a cutting station 38 wherein the sandwich is cut into individual tablets or wafers 36 .
- the carrier surface with the electrostatic charge carries a known amount of charge on its surface and the polarity of this charge is opposite to that of the powder particles suspended in the chamber.
- the charged particles migrate to the charged surface because of the attraction by the opposite nature of the charges. This migration of the particles continues until the charge on the carrier surface is neutralized.
- the actual amount of powder mass transferred to the carrier surface is a function of the mass-to-charge ratio of the charged particles. Although it is difficult to achieve a linear relationship between the mass and the actual charge, it is possible to establish a fixed relationship between the surface area of the powder particles and the charge the powder particle is carrying at charge saturation. However, the surface area of a mixed group of powder particles of different sizes and shapes can be extremely difficult to calculate mathematically, particularly when the shapes are irregular, (e.g.
- the simplest method of determining the amount and area of charge to attract a given weight of particles is to estimate the correct area and charge and then apply the estimated charge to the estimated area on the carrier surface 24 and expose this selectively charged area to a mass of powder which has been ionized in the ionizing step.
- the amount of powder deposited can then be readily measured at the discharge step. Thereafter, either the size of the charged area or the amount of charge applied to the area at the charging station 25 can be adjusted upwardly or downwardly to provide the correct amount of charge, both in area and charge intensity, for picking up a desired weight of oppositely charged powder.
- larger quantities of medication may be deposited.
- a feature and advantage of the present invention is to produce carefully controlled doses of controlled release medication. Electrostatic metering and packaging as above described permits exact dosing. And, by employing selected porous, permeable or semi-permeable membranes for encapsulating the powdered medicine aliquots, drug release rate and also site of drug release can be determined by adjusting membrane material and/or membrane thickness.
- the membranes should be formed of ingestible materials having a selected permeability porosity to fluids at a selected site or sites within the alimentary canal, so as to permit controlled release of the medication.
- one or both membranes 29 , 34 may comprise acid-dissolvable materials when it is desired to release the medication into the stomach or the membranes 29 , 34 may be alkaline-dissolvable materials at differing pH's to release into chosen locations within the intestine. Porosity, membrane thickness, etc., may be selected to provide desired rate of dissolution at the site of interest.
- the invention is susceptible to modification.
- a two-component controlled release tablet 48 may be formed (see FIG. 4) incorporating two different powdered medicines 50 , 52 , encapsulated between membranes 29 and 34 for simultaneous controlled release.
- two different drugs 60 , 62 may be layered on one another, separated by a membrane 64 so the two medications may be delivered sequentially either in the same location, or in different locations within the alimentary canal.
- Another feature and advantage of the multi-drug tablet of FIG. 4 and FIG. 5, as will be discussed in detail herein below, is that two normally incompatible drugs may be to be safely packaged in a single tablet.
- the invention is susceptible to modification.
- individual doses may be formed by electrostatic deposition in accordance with U.S. Pat. No. 5,714,007.
- the tablet 70 may incorporate an adhesive layer 72 such as a mucosal adhesive, which in turn is covered by an acid or alkaline dissolvable protective membrane 74 , which dissolves at a selected site allowing the adhesive to adhere, for example, to the intestinal wall, thereby increasing residence time of the medication in a chosen location.
- an acid or alkaline activatable adhesive may be applied to the outer surface of the tablet.
- the membrane may be a material which expands on contact with the acid or alkaline in the alimentary canal and becomes more porous whereby to slowly release medication in a chosen location within the alimentary canal.
- a particular feature and advantage of the present invention is that it permits packaging, within a single tablet of two or more different drugs normally considered to be incompatible. Certain drugs are known to cause undesirable side effects which need to be countered by a second drug.
- Omeprazole 1 which finds substantial utility as an oral antiulcer agent, also is known to block the release of B12 from its protein binding site in food. This can lead to pernicious anemia.
- the present invention permits packaging of time-release Omeprazole with Vitamin B12 in an appropriate dosage of, e.g. 25 ⁇ gm-1 mg. After taking the medication, one membrane will dissolve allowing absorption of the B12, while the remaining membrane package carrying the Omeprazole will pass into the small intestine where the drug is released and absorbed.
- the invention is susceptible to modification.
- the membranes have been described as being preformed, permeable, semipermeable or porous material, one or both membranes could be formed in place from a gel or liquid.
- the ability to accurately place the dose of medication onto a plurality of substrates and seal the dose with other membranes in accordance with the present invention allows for the fabrication of many different dosage forms; by altering the substrates and encapsulating material a single unit dose form can be fabricated with a plurality of different drugs in different coverings, membranes and barriers. This will provide a single dosage form with multiple active ingredients each being delivered to the appropriate site for absorption.
- two or more active medicaments may be combined in a single delivery container, i.e.
- the active ingredients are segregated from one another in a compartmentalized capsule 100 .
- two or more tablets 102 , 104 each containing only one active ingredient could be placed in a larger absorbable capsule or encased in a larger tablet 106 .
- two or more active ingredients could each be formulated as encapsulated particles 108 A, 108 B, and the encapsulated mixed particles placed in a capsule 110 where the only contact is between the particle inert coatings, etc.
- Omeprazole 1 and analogs and isomers are an inhibitor of gastric secretion and also inhibits the absorption of certain drugs/compounds that require stomach acid such as Vitamin B12, the deficit of which results in pernicious anemia. A combination of B12 with Omeprazole would eliminate the potential problem.
- Valacyclovir 2 and analogs are used to treat Herpes Zoster. It is well known that two drugs Cimetidine 3 and Probenecid 4 both increase the AUC (area under curve) and Cmax. A combination drug can be constructed with a combination of either one or more of these components to provide more efficacy.
- Enalapril 5 and analogs and isomers is an ACE inhibitor used for the treatment of hypertension.
- This drug has been used with the following and analogs and isomers beta adrenegic-blocking agents, methyldopa, nitrate, calcium blocking agents, hydrazinc, Prazosin 6 and Digoxin 7 without clinically significant side effects.
- beta adrenegic-blocking agents beta adrenegic-blocking agents
- methyldopa methyldopa
- nitrate calcium blocking agents
- hydrazinc Prazosin 6 and Digoxin 7
- One or more of these agents may be combined with Enalapril to improve the compliance of patient with hypertension and hypertension and other cardiac diseases.
- Ketoconazole 8 and analogs and isomers is used to treat fungal infections.
- One of the side effects is the reduction of Testosterone. This side effect could be helped by the combination of Testosterone or one of its isomers or analogs to overcome the side effect.
- Omeprazolel and analogs and isomers is also used in combination with Clarithoromycin 1 for ulcer treatment. These two drugs may be combined as a single dose for patient compliance.
- Tamoxifen 10 and analogs and isomers used in treatment of breast cancer has a +/ ⁇ 30% incident of water retention with weight gain>5%. This can be a disturbing consequence for patients with an even more disturbing disease.
- Isotretinoin 11 and analogs and isomers used for the treatment of postular acne has a severe danger if taken by a woman who is pregnant.
- the incorporation of oral contraceptive medication would eliminate the potential for pregnancy while medicated.
- Metformin HCl 12 and analogs and isomers are hypoglycenic agents which have been used in combination with Solfonylureal 13 and analogs and isomers to treat Type 2 Diabetes. These two agents act in different ways on reducing glucose levels. A combination would be helpful for those patients requiring more aggressive oral therapy for their diabetes.
- combination drugs including some of the above-listed combination drugs, also may be blended and packaged in a single tablet or capsule, when chemical interaction is not a problem.
- the present invention also allows for the rapid production of different dosage medications using the same active ingredient, and allows for the development of medications with longer resident time.
Abstract
Description
- The present invention relates to the packaging of dry powders and particularly to the metering and packaging of precise quantities of pharmaceuticals and drugs for medical uses. The invention has particular utility in the metering and packaging of dry powders, particularly precise amounts of dry powder pharmaceuticals and drugs, and will be described in connection with such utility, although other utilities are contemplated.
- The convenience of administering a single dose of a medication which releases multiple active ingredients in a controlled fashion and in a chosen location over an extended period of time, as opposed to the administration of a number of single doses at regular intervals, has long been recognized in the pharmaceutical arts. The advantage to the patient and clinician in having consistent and uniform blood levels of medication over an extended period of time are likewise recognized. The advantages of a variety of controlled-release dosage forms are well known. Among the most important advantages are: (1) increased contact time for the drug to allow for local activity in the stomach, small intestine, colon, or other locus of activity; (2) increased and more efficient absorption for drugs which have specific absorption sites; (3) the ability to reduce the number of dosages per period of time; (4) employment of less total drug; (5) minimization or elimination of local and/or systemic side effects; (6) minimization of drug accumulation associated with chronic dosing; (7) improved efficiency and safety of treatment; (8) reduced fluctuation of drug level; and (9) better patient compliance with overall disease management.
- Additionally, many experts believe controlled release drug delivery has many important non-therapeutic ramifications as well, including a financial saving to the patient in terms of fewer lost work days, reduced hospitalization and fewer visits to the physician.
- It is known that certain design parameters are critical to proper drug delivery. Typically, they are: (1) delivering the drug to the target tissue; (2) supplying the drug for a predetermined period of time; and (3) fabricating a delivery system that provides drug in the desired spatial and temporal pattern. Controlled release drug delivery systems are intended to utilize these parameters to achieve the aforementioned advantages as compared to conventional pharmaceutical dosing.
- Previously direct placement of medication onto a substrate generally was limited to medical placement of large doses or required technology where the active pharmaceutical was mixed with the substrate or matrix to provide differential delivery, or coated with a material with desired release characteristics.
- As used herein “controlled-release” is used to describe a system, i.e. method and materials for making an active ingredient available to the patient in accordance with a preselected condition, i.e. time, site, etc Controlled-release includes the use of instantaneous release, delayed release and sustained release. “Instantaneous release” refers to immediate release to the patient. “Delayed release” means the active ingredient is not made available until some time delay after administration. Typically, dosages are administered by oral ingestion, although other forms of administration are contemplated in accordance with the present invention. “Sustained release” refers to release of active ingredient whereby the level of active ingredient available to the patient is maintained at some level over a period of time. The method of effecting each type of release can be varied. For example, the active-ingredient can be placed on a semi-permeable membrane having predetermined diffusion, dissolution, erosion or breakdown characteristics.
- Alternatively, the active ingredient can be masked by a coating, a laminate, etc. Regardless of the method of providing the desired release pattern, the present invention contemplates delivery of a controlled-release system which utilizes one or more of the “release” methods and materials. Moreover, the present invention advantageously can be employed in the development of multiple different release system(s).
- The patent and scientific literature is replete with various sustained release (SR) methods and materials. For common methods of obtaining SR systems, see “Sustained and Controlled Release Drug Delivery Systems,” Robinson, Joseph R., Ed., PP 138-171, 1978, Marcel Dekker, Inc. New York, N.Y. For example it is known to fill polymeric capsules with a solid, liquid, suspension or gel containing a therapeutic agent which is slowly released by diffusion through the capsule walls. Heterogeneous matrices, for example, compressed tablets, control the release of their therapeutic agents either by diffusion, erosion of the matrix or a combination of both. Other SR systems focus on the fabrication of laminates of polymeric material and therapeutic agent which are then formed into a sandwich, relying on different diffusion or erosion rates to control release of the therapeutic agent. Liquid-liquid encapsulation in a viscous syrup-like solution of polymer also has been known to be useful in controlling release of the therapeutic agent. Additionally, it is generally known that heterogeneous dispersions or solutions of therapeutic agents in water-swellable hydrogen matrices are useful in controlling the release of the agent by slow surface-to-center swelling of the matrix and subsequent diffusion of the agent from the water-swollen part of the matrix.
- During dissolution of a controlled-release matrix tablet, the dosage form generally remains as a non-disintegrating, slowly eroding entity from which the therapeutic agent leaches out, through a diffusion controlled process. Conventional SR formulations are generally designed to release their active ingredients over an extended period of time, usually 8-24 hours. Conventional SR formulations use waxes or hydrophilic gums as the primary drug carriers to prolong the release of the active ingredients.
- Starch USP (potato or corn) is commonly used as a component in conventional tablet or hard shell capsule formulations.
- The existing sustained release technologies generally involve relatively complicated formulations and manufacturing processes which often are difficult and expensive to precisely control. For example, one well known SR delivery system, OROS, marketed by the Alza Corporation, involves laser drilling through a tablet to create passages for the release of the drug from the tablet core. In controlled release technologies, it is desirable to be able- to incorporate the active ingredient in its controlled-release pattern in a single dosage unit without deteriorating the active ingredient. Moreover, the dosage unit should be able to deliver the system without interfering with its release pattern.
- Various methods have been devised to enable controlled-release systems to be delivered to a patient without destruction of the delivery system during manufacturing, handling and distribution. For example, controlled-release systems have been provided in the form of beads or particles which are packaged in a gelatin capsule for oral dosage. This method of delivery of the controlled-release system prevents damage to the coating on the beads.
- Furthermore, when controlled-release active ingredients are incorporated in compression tablets, it may be difficult for many people to swallow such tablets. Moreover; dissolution of high compression tablets often initially is slow and erratic and may result in localized hot spots of alimentary tract irritation where disintegration and release of the active ingredient finally occurs. And, present systems do not allow for the accurate deposition of doses of powdered medication onto different substrates either in single packets, layered packet, or multipackets on the same plane of the base substrate. The present invention overcomes the disadvantages of the prior art by offering a simple and inexpensive means of incorporating active ingredient (the drug) with a multitude of controlled-release systems.
- In our earlier U.S. Pat. No. 5,699,649, granted Dec. 23, 1997, we describe a method and apparatus for packaging microgram quantities of fine powders such as pharmaceuticals using electrostatic phototechnology techniques. More particularly, as described in our aforesaid U.S. Pat. No. 5,699,649, the ability of powders to acquire an electrical charge advantageously is utilized for precisely measuring exact microgram quantities of the powder, whereupon these exact microgram quantities are then placed in individual containers, and the containers sealed.
- Electrostatic charge has been employed to attract a given quantity of powder to a surface. An example of this is the laser printer or the electrostatic copy device where a drum is charged and toner particles are attracted and held in position by the charge. The charge on the drum is neutralized by the attracted toner powder, thus limiting the amount of toner in accordance with the charge image on the drum. The charged powder on the printer drum is then transferred to a sheet of paper or other carrier to give a final image. In our U.S. Pat. No. 5,699,649, electrostatic charge technology is employed for transferring a predetermined amount of a finely powdered pharmaceutical or drug to a carrier or an intermediate such as a drum, carrying a charge of predetermined intensity and area, rotating the charged drum surface, carrying the predetermined amount of powdered pharmaceutical or drug on its surface, to a transfer station where the charge is overcome and the dry powder is transferred to a package which is then sealed. In lieu of a drum, a belt, or other movable surface is charged to a given potential in a localized area. Alternatively, a predetermined amount of powdered pharmaceutical or drug may be deposited directly in a package using electrostatic charge technology.
- When a given amount of a powdered pharmaceutical or drug is to be packaged, the charge and area of charge can be determined experimentally for each dose of pharmaceutical or drug and each particle size distribution. This can be done by controlling either the charged area for a given charge density or the total electrostatic charge on any individual charged area. These conditions can be adjusted to provide essentially the exact desired amount of the particular pharmaceutical or drug to be transferred at the transfer station.
- In our U.S. application Ser. No. 09/097,104, we describe another electrostatic charge technology which may be adopted to be used for measuring and packaging unit doses of a pharmaceutical or drug in a readily ingestible form, i.e. as a tablet or capsule. The technology thus described also permits reproducible precise measurement and packaging of a pharmaceutical or drug, and which may be scaled from laboratory to pilot plant to full scale production without the need for recertification.
- In accordance with one aspect of the present invention, controlled quantities of powdered medication are formed in controlled release packages using electrostatic metering technology. The present invention also provides, in another aspect, combination medication delivery systems in which the active ingredients are segregated from one another
- Further features and objects of the present invention will become clear from the following detailed description taken in conjunction with the accompanying drawings, wherein like numerals depict like parts, and wherein:
- FIG. 1 is a schematic flow diagram showing the various steps involved in practicing the present invention;
- FIG. 2 is an enlarged cross-sectional view of one embodiment of a controlled release tablet made in accordance with the present invention;
- FIG. 3 is a view, similar to FIG. 1, and showing alternative steps involved in practicing the present invention;
- FIG. 4 is a view, similar to FIG. 2, and showing an alternative form of a controlled release tablet made in accordance with the present invention;
- FIG. 5 is a view similar to FIG. 2, and showing yet another alternative embodiment of the present invention;
- FIG. 6 is a view, similar to FIG. 2, and showing yet another embodiment of the invention; and
- FIGS.7-9 are views similar to FIG. 2, and showing yet other embodiments of the present invention.
- Referring now to FIG. 1, there is a schematic flow diagram of the various pieces of equipment needed to perform in the total process from powder supply to packaged pharmaceutical or drug, i.e. in controlled release tablet form, containing a specified amount of pharmaceutical or drug powder in the tablet or package. At16 is indicated the pharmaceutical or drug powder supply which is fed into a
device 18 for creating an aerosol of the powder. Next the powder particles are ionized at 20. As will be indicated later, a number of these steps and pieces of equipment can be combined. At 24 is indicated a carrier surface capable of maintaining a space charge on its surface. This can be a plastic belt, for example, or a selenium drum of the type used in Xerox™ photocopiers. Thiscarrier surface 24 is passed through a chargingstation 25 where a predeterminedelectrostatic charge 25A (an electrostatic “image”) is created on a predetermined area of the transfer surface. This chargedsurface 25A then passes through astep 26 wherein powder is deposited on the carrier surface in asufficient amount 26A to neutralize the charge carried by the carrier surface. Thereafter, the carrier surface, carrying thepredetermined amount 26A of powder on its surface, is passed to apowder discharging device 30 which discharges thepowder 26A from thesurface 24 onto amembrane 29. Alternatively, the powder may be placed directly onto themembrane 29. Themembrane 29 containing its charge ofpowder 26A, then passes through a sealingstep 32 wherein asecond membrane 34 which may be porous, permeable or semi-permeable covers and seals the dischargedpowder 26A on themembrane 29. There is thus produced an aliquot ofpowdered medicine 26A sandwiched between semi-permeable orpermeable membranes - This sandwiched material is then passed to a cutting
station 38 wherein the sandwich is cut into individual tablets orwafers 36. - As mentioned previously in discussing FIG. 1, the carrier surface with the electrostatic charge carries a known amount of charge on its surface and the polarity of this charge is opposite to that of the powder particles suspended in the chamber. The charged particles migrate to the charged surface because of the attraction by the opposite nature of the charges. This migration of the particles continues until the charge on the carrier surface is neutralized.
- The actual amount of powder mass transferred to the carrier surface is a function of the mass-to-charge ratio of the charged particles. Although it is difficult to achieve a linear relationship between the mass and the actual charge, it is possible to establish a fixed relationship between the surface area of the powder particles and the charge the powder particle is carrying at charge saturation. However, the surface area of a mixed group of powder particles of different sizes and shapes can be extremely difficult to calculate mathematically, particularly when the shapes are irregular, (e.g. non-spherical, microcrystalline, etc.) As mentioned earlier, the simplest method of determining the amount and area of charge to attract a given weight of particles is to estimate the correct area and charge and then apply the estimated charge to the estimated area on the
carrier surface 24 and expose this selectively charged area to a mass of powder which has been ionized in the ionizing step. The amount of powder deposited can then be readily measured at the discharge step. Thereafter, either the size of the charged area or the amount of charge applied to the area at the chargingstation 25 can be adjusted upwardly or downwardly to provide the correct amount of charge, both in area and charge intensity, for picking up a desired weight of oppositely charged powder. Likewise, using the technology of our co-pending application Ser. No. 09/097,104, larger quantities of medication may be deposited. - A feature and advantage of the present invention is to produce carefully controlled doses of controlled release medication. Electrostatic metering and packaging as above described permits exact dosing. And, by employing selected porous, permeable or semi-permeable membranes for encapsulating the powdered medicine aliquots, drug release rate and also site of drug release can be determined by adjusting membrane material and/or membrane thickness.
- The membranes should be formed of ingestible materials having a selected permeability porosity to fluids at a selected site or sites within the alimentary canal, so as to permit controlled release of the medication. By way of example, one or both
membranes membranes - The invention is susceptible to modification. For example, referring to FIGS. 3 and 4 by adding a second powdered medicine supply and discharge station (shown generally at40), a two-component controlled
release tablet 48 may be formed (see FIG. 4) incorporating two differentpowdered medicines membranes - Alternatively, as shown in FIG. 5, two
different drugs membrane 64 so the two medications may be delivered sequentially either in the same location, or in different locations within the alimentary canal. Another feature and advantage of the multi-drug tablet of FIG. 4 and FIG. 5, as will be discussed in detail herein below, is that two normally incompatible drugs may be to be safely packaged in a single tablet. - The invention is susceptible to modification. For example, individual doses may be formed by electrostatic deposition in accordance with U.S. Pat. No. 5,714,007.
- Other possibilities are possible. For example, referring to FIG. 6, the
tablet 70 may incorporate anadhesive layer 72 such as a mucosal adhesive, which in turn is covered by an acid or alkaline dissolvableprotective membrane 74, which dissolves at a selected site allowing the adhesive to adhere, for example, to the intestinal wall, thereby increasing residence time of the medication in a chosen location. Alternatively, an acid or alkaline activatable adhesive may be applied to the outer surface of the tablet. In yet another possibility, the membrane may be a material which expands on contact with the acid or alkaline in the alimentary canal and becomes more porous whereby to slowly release medication in a chosen location within the alimentary canal. - As mentioned above, a particular feature and advantage of the present invention is that it permits packaging, within a single tablet of two or more different drugs normally considered to be incompatible. Certain drugs are known to cause undesirable side effects which need to be countered by a second drug. For example, Omeprazole1 which finds substantial utility as an oral antiulcer agent, also is known to block the release of B12 from its protein binding site in food. This can lead to pernicious anemia. The present invention permits packaging of time-release Omeprazole with Vitamin B12 in an appropriate dosage of, e.g. 25 μgm-1 mg. After taking the medication, one membrane will dissolve allowing absorption of the B12, while the remaining membrane package carrying the Omeprazole will pass into the small intestine where the drug is released and absorbed.
- The invention is susceptible to modification. For example, while the membranes have been described as being preformed, permeable, semipermeable or porous material, one or both membranes could be formed in place from a gel or liquid. The ability to accurately place the dose of medication onto a plurality of substrates and seal the dose with other membranes in accordance with the present invention, allows for the fabrication of many different dosage forms; by altering the substrates and encapsulating material a single unit dose form can be fabricated with a plurality of different drugs in different coverings, membranes and barriers. This will provide a single dosage form with multiple active ingredients each being delivered to the appropriate site for absorption. Alternatively, two or more active medicaments may be combined in a single delivery container, i.e. pill, capsule or caplet without actually mixing the two or more ingredients. For example, referring to FIG. 7, the active ingredients are segregated from one another in a
compartmentalized capsule 100. Alternatively, two ormore tablets larger tablet 106. Or, as shown in FIG. 9, two or more active ingredients could each be formulated as encapsulatedparticles capsule 110 where the only contact is between the particle inert coatings, etc. - There are many drugs which could benefit from combinations to improve patient benefit. However, with many active ingredients, there is a question of chemical interaction. Thus, several drugs are normally prescribed as separate tablets or capsules which presents a problem in terms of patient compliance, e.g. TB triple therapy, AIDS multi-drug therapy, anti-infectives, etc. Also, delivery of two or more active medicaments could reduce side effects, and/or improve therapeutic response which may in turn permit a decrease in the required dosage. By way of example, we provide the following combinations:
- (1) Omeprazole1 and analogs and isomers—As noted above Omeprazole is an inhibitor of gastric secretion and also inhibits the absorption of certain drugs/compounds that require stomach acid such as Vitamin B12, the deficit of which results in pernicious anemia. A combination of B12 with Omeprazole would eliminate the potential problem.
- (2) Valacyclovir2 and analogs and is used to treat Herpes Zoster. It is well known that two drugs Cimetidine3 and Probenecid4 both increase the AUC (area under curve) and Cmax. A combination drug can be constructed with a combination of either one or more of these components to provide more efficacy.
- (3) Enalapril5 and analogs and isomers is an ACE inhibitor used for the treatment of hypertension. This drug has been used with the following and analogs and isomers beta adrenegic-blocking agents, methyldopa, nitrate, calcium blocking agents, hydrazinc, Prazosin6 and Digoxin7 without clinically significant side effects. One or more of these agents may be combined with Enalapril to improve the compliance of patient with hypertension and hypertension and other cardiac diseases.
- (4) Ketoconazole8 and analogs and isomers is used to treat fungal infections. One of the side effects is the reduction of Testosterone. This side effect could be helped by the combination of Testosterone or one of its isomers or analogs to overcome the side effect.
- (5) Omeprazolel and analogs and isomers is also used in combination with Clarithoromycin1 for ulcer treatment. These two drugs may be combined as a single dose for patient compliance.
- (6) Tamoxifen10 and analogs and isomers used in treatment of breast cancer has a +/−30% incident of water retention with weight gain>5%. This can be a disturbing consequence for patients with an even more disturbing disease. The addition of a diuretic or combination diuretic to form a single dosage form for reduction in side effect and compliance.
- (7) Isotretinoin11 and analogs and isomers used for the treatment of postular acne has a severe danger if taken by a woman who is pregnant. The incorporation of oral contraceptive medication would eliminate the potential for pregnancy while medicated.
- (8) Metformin HCl12 and analogs and isomers are hypoglycenic agents which have been used in combination with Solfonylureal13 and analogs and isomers to treat
Type 2 Diabetes. These two agents act in different ways on reducing glucose levels. A combination would be helpful for those patients requiring more aggressive oral therapy for their diabetes. - It should be noted that certain combination drugs, including some of the above-listed combination drugs, also may be blended and packaged in a single tablet or capsule, when chemical interaction is not a problem.
- The present invention also allows for the rapid production of different dosage medications using the same active ingredient, and allows for the development of medications with longer resident time.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/756,124 US7404968B2 (en) | 1999-08-18 | 2004-01-12 | Metering and packaging of controlled release medication |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/376,619 US6428809B1 (en) | 1999-08-18 | 1999-08-18 | Metering and packaging of controlled release medication |
US10/044,612 US6702683B2 (en) | 1999-08-18 | 2002-01-11 | Metering and packaging of controlled release medication |
US10/756,124 US7404968B2 (en) | 1999-08-18 | 2004-01-12 | Metering and packaging of controlled release medication |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/044,612 Continuation US6702683B2 (en) | 1999-08-18 | 2002-01-11 | Metering and packaging of controlled release medication |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040142036A1 true US20040142036A1 (en) | 2004-07-22 |
US7404968B2 US7404968B2 (en) | 2008-07-29 |
Family
ID=23485760
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/376,619 Expired - Lifetime US6428809B1 (en) | 1999-08-18 | 1999-08-18 | Metering and packaging of controlled release medication |
US10/044,612 Expired - Fee Related US6702683B2 (en) | 1999-08-18 | 2002-01-11 | Metering and packaging of controlled release medication |
US10/756,124 Expired - Lifetime US7404968B2 (en) | 1999-08-18 | 2004-01-12 | Metering and packaging of controlled release medication |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/376,619 Expired - Lifetime US6428809B1 (en) | 1999-08-18 | 1999-08-18 | Metering and packaging of controlled release medication |
US10/044,612 Expired - Fee Related US6702683B2 (en) | 1999-08-18 | 2002-01-11 | Metering and packaging of controlled release medication |
Country Status (11)
Country | Link |
---|---|
US (3) | US6428809B1 (en) |
EP (2) | EP2052697A1 (en) |
JP (1) | JP2003517351A (en) |
AT (1) | ATE429190T1 (en) |
AU (1) | AU6909800A (en) |
CA (1) | CA2380596A1 (en) |
DE (1) | DE60042076D1 (en) |
DK (1) | DK1207809T3 (en) |
ES (1) | ES2323846T3 (en) |
PT (1) | PT1207809E (en) |
WO (1) | WO2001012103A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040185119A1 (en) * | 2003-02-26 | 2004-09-23 | Theuer Richard C. | Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency |
US20090010997A1 (en) * | 2006-03-07 | 2009-01-08 | Orahealth Corporation | Multi-layer medical patch with impermeable center |
US20090087483A1 (en) * | 2007-09-27 | 2009-04-02 | Sison Raymundo A | Oral dosage combination pharmaceutical packaging |
US20100143533A1 (en) * | 2007-08-03 | 2010-06-10 | Shaklee Corporation | Nutritional supplement system |
US8439033B2 (en) | 2007-10-09 | 2013-05-14 | Microdose Therapeutx, Inc. | Inhalation device |
US8991390B2 (en) | 2010-01-05 | 2015-03-31 | Microdose Therapeutx, Inc. | Inhalation device and method |
US9763989B2 (en) | 2007-08-03 | 2017-09-19 | Shaklee Corporation | Nutritional supplement system |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642236B1 (en) * | 1998-12-14 | 2003-11-04 | Cortendo Ab | Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis |
US6428809B1 (en) * | 1999-08-18 | 2002-08-06 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
EP1248595A4 (en) | 2000-01-20 | 2006-06-14 | Delsys Pharmaceutical Corp | Multi-step drug dosage forms |
GB0001449D0 (en) * | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
FR2816840B1 (en) * | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | MEDICINE BASED ON SUSTAINED RELEASE ANTI-HYPERCLYCEMIA MICROCAPSULES AND METHOD FOR PREPARING THE SAME |
FR2825023B1 (en) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | ANTIDIABETIC ORAL PHARMACEUTICAL FORM "ONE TAKEN PER DAY" INCLUDING BIGUANIDE AND AT LEAST ONE OTHER ACTIVE INGREDIENT |
US20040156903A1 (en) * | 2002-05-22 | 2004-08-12 | Abrams Andrew L.. | Metering and packaging of controlled release medication |
WO2002096347A2 (en) * | 2001-05-31 | 2002-12-05 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
US20070087048A1 (en) * | 2001-05-31 | 2007-04-19 | Abrams Andrew L | Oral dosage combination pharmaceutical packaging |
US6844048B2 (en) * | 2001-07-11 | 2005-01-18 | Sarnoff Corporation | Substrates for powder deposition containing conductive domains |
GB0118300D0 (en) * | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
US20040265323A1 (en) * | 2003-05-16 | 2004-12-30 | Mccormick Beth A. | Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof |
US7377277B2 (en) * | 2003-10-27 | 2008-05-27 | Oriel Therapeutics, Inc. | Blister packages with frames and associated methods of fabricating dry powder drug containment systems |
US20070277820A1 (en) * | 2003-10-27 | 2007-12-06 | Timothy Crowder | Blister packages and associated methods of fabricating dry powder drug containment systems |
US8210171B2 (en) | 2004-09-13 | 2012-07-03 | Oriel Therapeutics, Inc. | Tubular dry powder drug containment systems, associated inhalers and methods |
EP1836665B1 (en) | 2004-11-19 | 2013-01-16 | GlaxoSmithKline LLC | Method for customized dispensing of variable dose drug combination products for individualizing of therapies |
US7325903B2 (en) * | 2004-12-14 | 2008-02-05 | Palo Alto Research Center Incorporated | Quill-jet printer |
US7325987B2 (en) * | 2004-12-14 | 2008-02-05 | Palo Alto Research Center Incorporated | Printing method using quill-jet |
US7286149B2 (en) * | 2004-12-14 | 2007-10-23 | Palo Alto Research Center Incorporated | Direct xerography system |
US7342596B2 (en) * | 2004-12-14 | 2008-03-11 | Palo Alto Research Center Incorporated | Method for direct xerography |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US8730031B2 (en) | 2005-04-28 | 2014-05-20 | Proteus Digital Health, Inc. | Communication system using an implantable device |
CN101287411B (en) | 2005-04-28 | 2013-03-06 | 普罗秋斯生物医学公司 | Pharma-informatics system |
US8547248B2 (en) | 2005-09-01 | 2013-10-01 | Proteus Digital Health, Inc. | Implantable zero-wire communications system |
CA2625776A1 (en) * | 2005-10-14 | 2007-04-26 | Microdose Technologies, Inc. | Pharmaceutical packaging of an oral dosage combination |
WO2007078874A2 (en) * | 2005-12-30 | 2007-07-12 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
US20070254858A1 (en) * | 2006-04-27 | 2007-11-01 | Cronk Peter J | Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects |
US20070254025A1 (en) * | 2006-04-27 | 2007-11-01 | Cronk Peter J | Oral contraceptive and acne medication combination and treatment of acne with reduced side effects |
CN105468895A (en) | 2006-05-02 | 2016-04-06 | 普罗透斯数字保健公司 | Patient customized therapeutic regimens |
AU2007266574A1 (en) * | 2006-06-01 | 2007-12-06 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
SG174026A1 (en) | 2006-08-03 | 2011-09-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
ATE535057T1 (en) | 2006-10-17 | 2011-12-15 | Proteus Biomedical Inc | LOW VOLTAGE OSCILLATOR FOR MEDICAL FACILITIES |
SG175681A1 (en) | 2006-10-25 | 2011-11-28 | Proteus Biomedical Inc | Controlled activation ingestible identifier |
WO2008063626A2 (en) | 2006-11-20 | 2008-05-29 | Proteus Biomedical, Inc. | Active signal processing personal health signal receivers |
CA2676407A1 (en) | 2007-02-01 | 2008-08-07 | Proteus Biomedical, Inc. | Ingestible event marker systems |
CN101636865B (en) | 2007-02-14 | 2012-09-05 | 普罗秋斯生物医学公司 | In-body power source having high surface area electrode |
US8932221B2 (en) | 2007-03-09 | 2015-01-13 | Proteus Digital Health, Inc. | In-body device having a multi-directional transmitter |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
DK2192946T3 (en) | 2007-09-25 | 2022-11-21 | Otsuka Pharma Co Ltd | In-body device with virtual dipole signal amplification |
EP3235491B1 (en) | 2008-03-05 | 2020-11-04 | Proteus Digital Health, Inc. | Multi-mode communication ingestible event markers and systems |
US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
SG10201702853UA (en) | 2008-07-08 | 2017-06-29 | Proteus Digital Health Inc | Ingestible event marker data framework |
AU2009281876B2 (en) | 2008-08-13 | 2014-05-22 | Proteus Digital Health, Inc. | Ingestible circuitry |
JP5411943B2 (en) | 2008-11-13 | 2014-02-12 | プロテウス デジタル ヘルス, インコーポレイテッド | Ingestible therapy activation system and method |
AU2009324536A1 (en) | 2008-12-11 | 2011-07-14 | Proteus Digital Health, Inc. | Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same |
US9659423B2 (en) | 2008-12-15 | 2017-05-23 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
TWI503101B (en) | 2008-12-15 | 2015-10-11 | Proteus Digital Health Inc | Body-associated receiver and method |
US9439566B2 (en) | 2008-12-15 | 2016-09-13 | Proteus Digital Health, Inc. | Re-wearable wireless device |
SG196787A1 (en) | 2009-01-06 | 2014-02-13 | Proteus Digital Health Inc | Ingestion-related biofeedback and personalized medical therapy method and system |
SG172847A1 (en) | 2009-01-06 | 2011-08-29 | Proteus Biomedical Inc | Pharmaceutical dosages delivery system |
TWI494108B (en) * | 2009-01-26 | 2015-08-01 | Nitec Pharma Ag | Glucocorticoid for manufacture of medicament in delayed-release dosage form for treatment of severe nocturnal asthma |
NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
GB2480965B (en) | 2009-03-25 | 2014-10-08 | Proteus Digital Health Inc | Probablistic pharmacokinetic and pharmacodynamic modeling |
SG10201810784SA (en) | 2009-04-28 | 2018-12-28 | Proteus Digital Health Inc | Highly Reliable Ingestible Event Markers And Methods For Using The Same |
US9149423B2 (en) | 2009-05-12 | 2015-10-06 | Proteus Digital Health, Inc. | Ingestible event markers comprising an ingestible component |
WO2011022732A2 (en) | 2009-08-21 | 2011-02-24 | Proteus Biomedical, Inc. | Apparatus and method for measuring biochemical parameters |
TWI517050B (en) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | System for supply chain management |
UA109424C2 (en) | 2009-12-02 | 2015-08-25 | PHARMACEUTICAL PRODUCT, PHARMACEUTICAL TABLE WITH ELECTRONIC MARKER AND METHOD OF MANUFACTURING PHARMACEUTICAL TABLETS | |
CN102946798A (en) | 2010-02-01 | 2013-02-27 | 普罗秋斯数字健康公司 | Data gathering system |
TWI638652B (en) | 2010-04-07 | 2018-10-21 | 波提亞斯數位康健公司 | Miniature ingestible device |
TWI557672B (en) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device |
CN110391028A (en) | 2010-08-13 | 2019-10-29 | 智能医学公司 | System and method for producing personalized customization drug products |
WO2012071280A2 (en) | 2010-11-22 | 2012-05-31 | Proteus Biomedical, Inc. | Ingestible device with pharmaceutical product |
EP2654658A4 (en) | 2010-12-23 | 2016-04-06 | Tailorpill Technologies Llc | System and methods for personalized pill compounding |
JP2014514032A (en) | 2011-03-11 | 2014-06-19 | プロテウス デジタル ヘルス, インコーポレイテッド | Wearable personal body-related devices with various physical configurations |
US8834411B2 (en) | 2011-04-06 | 2014-09-16 | Mystic Pharmaceuticals, Inc. | Medical devices for dispensing powders |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
CN103827914A (en) | 2011-07-21 | 2014-05-28 | 普罗秋斯数字健康公司 | Mobile communication device, system, and method |
EP2748685A4 (en) | 2011-08-27 | 2015-05-20 | Daniel L Kraft | Portable drug dispenser |
WO2013062570A1 (en) * | 2011-10-28 | 2013-05-02 | Hewlett-Packard Development Company, L.P. | Apparatus and method for producing controlled dosage of bioactive agent |
US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
BR112015001388A2 (en) | 2012-07-23 | 2017-07-04 | Proteus Digital Health Inc | techniques for making ingestible event markers comprising an ingestible component |
AU2013331417B2 (en) | 2012-10-18 | 2016-06-02 | Proteus Digital Health, Inc. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
TWI659994B (en) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | Highly-swellable polymeric films and compositions comprising the same |
JP6498177B2 (en) | 2013-03-15 | 2019-04-10 | プロテウス デジタル ヘルス, インコーポレイテッド | Identity authentication system and method |
US10175376B2 (en) | 2013-03-15 | 2019-01-08 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
JP6511439B2 (en) | 2013-06-04 | 2019-05-15 | プロテウス デジタル ヘルス, インコーポレイテッド | Systems, devices, and methods for data collection and outcome assessment |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
EP3047618B1 (en) | 2013-09-20 | 2023-11-08 | Otsuka Pharmaceutical Co., Ltd. | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
WO2015044722A1 (en) | 2013-09-24 | 2015-04-02 | Proteus Digital Health, Inc. | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
US10653622B1 (en) * | 2015-04-13 | 2020-05-19 | Pharmacoustics Technologies LLC | Individualized solid dosage products and a system and method for the globally integrated pharmaceutical manufacturing and its monitoring thereof |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
KR102051875B1 (en) | 2016-07-22 | 2019-12-04 | 프로테우스 디지털 헬스, 인코포레이티드 | Electromagnetic detection and detection of ingestible event markers |
AU2017348094B2 (en) | 2016-10-26 | 2022-10-13 | Otsuka Pharmaceutical Co., Ltd. | Methods for manufacturing capsules with ingestible event markers |
TW202110431A (en) | 2019-05-17 | 2021-03-16 | 美商癌症預防製藥股份有限公司 | Methods for treating familial adenomatous polyposis |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069084A (en) * | 1975-12-15 | 1978-01-17 | Hoffmann-La Roche Inc. | Novel dosage form |
US4182447A (en) * | 1977-07-27 | 1980-01-08 | Ira Kay | Device for storing, transporting and mixing reactive ingredients |
US4197289A (en) * | 1975-12-15 | 1980-04-08 | Hoffmann-La Roche Inc. | Novel dosage forms |
US4349531A (en) * | 1975-12-15 | 1982-09-14 | Hoffmann-La Roche Inc. | Novel dosage form |
US4772470A (en) * | 1985-04-27 | 1988-09-20 | Nitto Electric Industrial Co., Ltd. | Oral bandage and oral preparations |
US4795644A (en) * | 1987-08-03 | 1989-01-03 | Merck & Co., Inc. | Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins |
US5055306A (en) * | 1987-10-22 | 1991-10-08 | Aps Research Limited | Sustained-release formulations |
US5074426A (en) * | 1986-11-13 | 1991-12-24 | Warner-Lambert Company | Dividable capsule |
US5075114A (en) * | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
US5129572A (en) * | 1990-03-23 | 1992-07-14 | W. C. Heraeus Gmbh | Process for the manufacture of a metallic composite wire |
US5207705A (en) * | 1988-12-08 | 1993-05-04 | Brigham And Women's Hospital | Prosthesis of foam polyurethane and collagen and uses thereof |
US5629316A (en) * | 1993-06-30 | 1997-05-13 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
US5672359A (en) * | 1993-07-21 | 1997-09-30 | The University Of Kentucky Research Foundation | Multicompartment hard capsule with control release properties |
US5699649A (en) * | 1996-07-02 | 1997-12-23 | Abrams; Andrew L. | Metering and packaging device for dry powders |
US5827538A (en) * | 1993-07-22 | 1998-10-27 | Pfizer Inc. | Osmotic devices having vapor-permeable coatings |
US5960609A (en) * | 1998-06-12 | 1999-10-05 | Microdose Technologies, Inc. | Metering and packaging method and device for pharmaceuticals and drugs |
US6074688A (en) * | 1995-06-06 | 2000-06-13 | Delsys Pharmaceautical Corporation | Method for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US6197331B1 (en) * | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6350468B1 (en) * | 1997-12-17 | 2002-02-26 | Axcan Pharma Inc. | Double capsule for the administration of active principles in multiple therapies |
US6428809B1 (en) * | 1999-08-18 | 2002-08-06 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
US20040185100A1 (en) * | 2003-03-03 | 2004-09-23 | Sprl Franpharma | Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin |
US20040224020A1 (en) * | 2002-12-18 | 2004-11-11 | Schoenhard Grant L. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
US20050053649A1 (en) * | 2003-09-08 | 2005-03-10 | Anne-Marie Chalmers | Medication delivery device |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3241625A (en) | 1963-07-24 | 1966-03-22 | Howe Richardson Scale Co | Material feeding |
GB1054160A (en) | 1964-12-21 | |||
US3977323A (en) | 1971-12-17 | 1976-08-31 | Electroprint, Inc. | Electrostatic printing system and method using ions and liquid aerosol toners |
US3889636A (en) | 1972-08-02 | 1975-06-17 | Willoughby Arthur Smith | Coating of substrates with particle materials |
FR2258632B2 (en) | 1974-01-21 | 1976-10-08 | Rhone Poulenc Ind | |
US4021587A (en) | 1974-07-23 | 1977-05-03 | Pram, Inc. | Magnetic and electrostatic transfer of particulate developer |
US3999119A (en) | 1975-03-26 | 1976-12-21 | Xerox Corporation | Measuring toner concentration |
JPS533348A (en) | 1976-06-30 | 1978-01-13 | Konishiroku Photo Ind Co Ltd | Process and device for controlling toner density of developer liquid |
US4071169A (en) | 1976-07-09 | 1978-01-31 | Dunn John P | Electrostatic metering device |
US4170287A (en) | 1977-04-18 | 1979-10-09 | E. I. Du Pont De Nemours And Company | Magnetic auger |
US4255777A (en) | 1977-11-21 | 1981-03-10 | Exxon Research & Engineering Co. | Electrostatic atomizing device |
JPS5497040A (en) | 1978-01-17 | 1979-07-31 | Canon Inc | Developing agent conveyor |
JPS5619723U (en) | 1979-07-23 | 1981-02-21 | ||
US4339428A (en) * | 1980-08-18 | 1982-07-13 | Bristol-Myers Company | Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component |
US4379969A (en) | 1981-02-24 | 1983-04-12 | Dennison Manufacturing Company | Corona charging apparatus |
US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
DK152744C (en) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL PERORAL POLYDEPOT PREPARATION |
CA1190593A (en) | 1983-02-01 | 1985-07-16 | Paul E. Plasschaert | Corona device |
US4555174A (en) | 1983-12-19 | 1985-11-26 | Minnesota Mining And Manufacturing Company | Magnetically attractable developer material transport apparatus |
US4626876A (en) | 1984-01-25 | 1986-12-02 | Ricoh Company, Ltd. | Solid state corona discharger |
US4594901A (en) | 1984-11-09 | 1986-06-17 | Kimberly-Clark Corporation | Electrostatic flow meter |
CA1224240A (en) | 1984-12-24 | 1987-07-14 | Andrzej Maczuszenko | Ion generator structure |
US4848267A (en) | 1985-10-25 | 1989-07-18 | Colorocs Corporation | Apparatus for removal and addition of developer to a toner module |
JPH01141061A (en) | 1987-11-27 | 1989-06-02 | Fuji Xerox Co Ltd | Electrical discharge head |
US5009894A (en) * | 1988-03-07 | 1991-04-23 | Baker Cummins Pharmaceuticals, Inc. | Arrangement for and method of administering a pharmaceutical preparation |
JPH0217137U (en) * | 1988-07-21 | 1990-02-05 | ||
US4878454A (en) | 1988-09-16 | 1989-11-07 | Behr Industrial Equipment Inc. | Electrostatic painting apparatus having optically sensed flow meter |
DE3907387A1 (en) | 1989-03-08 | 1990-09-13 | Singer Hermann | METHOD FOR MEASURING PARTICLES IN POLYDISPERSE SYSTEMS AND OF PARTICLE CONCENTRATIONS OF MONODISPERS AEROSOLS AND MEASURING DEVICE FOR IMPLEMENTING THE METHOD |
JPH066149B2 (en) * | 1989-03-16 | 1994-01-26 | 株式会社菊水製作所 | Nucleated molded product |
CA2058764A1 (en) | 1989-04-28 | 1990-10-29 | Peter D. Hodson | Dry powder inhalation device |
US5005516A (en) | 1989-12-01 | 1991-04-09 | Eastman Kodak Company | Device for aiding in measuring pigmented marking particle level in a magnetic brush development apparatus |
US5204055A (en) | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
US5102045A (en) | 1991-02-26 | 1992-04-07 | Binks Manufacturing Company | Apparatus for and method of metering coating material in an electrostatic spraying system |
JPH04277126A (en) | 1991-02-28 | 1992-10-02 | Yamaishi:Kk | Conveyer for magnetic powder |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5421816A (en) | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
GB9223144D0 (en) * | 1992-11-05 | 1992-12-16 | Scherer Corp R P | Controlled release device |
IT1264696B1 (en) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED |
JP2728847B2 (en) | 1993-07-23 | 1998-03-18 | 日本パーカライジング株式会社 | Powder flow rate measuring method and apparatus |
US5490962A (en) | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
JP3278273B2 (en) * | 1993-12-17 | 2002-04-30 | キヤノン株式会社 | Drug sustained release capsule |
PT797424E (en) * | 1994-12-16 | 2000-10-31 | Warner Lambert Co | PROCESS FOR THE ENCAPSULATION OF "CAPLETS" IN A CAPSULE AND FORMS OF SOLID DOSAGE BY SUCH PROCESS |
DE4446470A1 (en) * | 1994-12-23 | 1996-06-27 | Basf Ag | Process for the production of dividable tablets |
US5669973A (en) | 1995-06-06 | 1997-09-23 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing and retaining materials upon a substrate |
SE9600072D0 (en) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
US5858099A (en) | 1996-04-09 | 1999-01-12 | Sarnoff Corporation | Electrostatic chucks and a particle deposition apparatus therefor |
IT1289160B1 (en) * | 1997-01-08 | 1998-09-29 | Jagotec Ag | FULLY COATED PHARMACEUTICAL TABLET FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS WHICH PRESENT PROBLEMS OF |
SE9700642D0 (en) * | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Means and ways of preventing and treating the metabolic syndrome |
US5948483A (en) | 1997-03-25 | 1999-09-07 | The Board Of Trustees Of The University Of Illinois | Method and apparatus for producing thin film and nanoparticle deposits |
US6004625A (en) | 1997-06-16 | 1999-12-21 | Ibick Corporation | Method for adhering particles to an object by supplying air ions |
DE19730231A1 (en) | 1997-07-15 | 1999-01-21 | Abb Research Ltd | Process for electrostatic coating |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
EP1248595A4 (en) | 2000-01-20 | 2006-06-14 | Delsys Pharmaceutical Corp | Multi-step drug dosage forms |
WO2002096347A2 (en) | 2001-05-31 | 2002-12-05 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
KR101259414B1 (en) | 2012-03-20 | 2013-05-10 | 한국과학기술정보연구원 | System and method for constructing a database for product demand/supply network |
-
1999
- 1999-08-18 US US09/376,619 patent/US6428809B1/en not_active Expired - Lifetime
-
2000
- 2000-08-16 DK DK00957487T patent/DK1207809T3/en active
- 2000-08-16 WO PCT/US2000/022468 patent/WO2001012103A1/en active Application Filing
- 2000-08-16 AU AU69098/00A patent/AU6909800A/en not_active Abandoned
- 2000-08-16 AT AT00957487T patent/ATE429190T1/en not_active IP Right Cessation
- 2000-08-16 EP EP09000680A patent/EP2052697A1/en not_active Withdrawn
- 2000-08-16 EP EP00957487A patent/EP1207809B1/en not_active Expired - Lifetime
- 2000-08-16 CA CA002380596A patent/CA2380596A1/en not_active Abandoned
- 2000-08-16 PT PT00957487T patent/PT1207809E/en unknown
- 2000-08-16 JP JP2001516450A patent/JP2003517351A/en active Pending
- 2000-08-16 ES ES00957487T patent/ES2323846T3/en not_active Expired - Lifetime
- 2000-08-16 DE DE60042076T patent/DE60042076D1/en not_active Expired - Lifetime
-
2002
- 2002-01-11 US US10/044,612 patent/US6702683B2/en not_active Expired - Fee Related
-
2004
- 2004-01-12 US US10/756,124 patent/US7404968B2/en not_active Expired - Lifetime
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069084A (en) * | 1975-12-15 | 1978-01-17 | Hoffmann-La Roche Inc. | Novel dosage form |
US4197289A (en) * | 1975-12-15 | 1980-04-08 | Hoffmann-La Roche Inc. | Novel dosage forms |
US4349531A (en) * | 1975-12-15 | 1982-09-14 | Hoffmann-La Roche Inc. | Novel dosage form |
US4182447A (en) * | 1977-07-27 | 1980-01-08 | Ira Kay | Device for storing, transporting and mixing reactive ingredients |
US4772470A (en) * | 1985-04-27 | 1988-09-20 | Nitto Electric Industrial Co., Ltd. | Oral bandage and oral preparations |
US5074426A (en) * | 1986-11-13 | 1991-12-24 | Warner-Lambert Company | Dividable capsule |
US4795644A (en) * | 1987-08-03 | 1989-01-03 | Merck & Co., Inc. | Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins |
US5055306A (en) * | 1987-10-22 | 1991-10-08 | Aps Research Limited | Sustained-release formulations |
US5207705A (en) * | 1988-12-08 | 1993-05-04 | Brigham And Women's Hospital | Prosthesis of foam polyurethane and collagen and uses thereof |
US5129572A (en) * | 1990-03-23 | 1992-07-14 | W. C. Heraeus Gmbh | Process for the manufacture of a metallic composite wire |
US5075114A (en) * | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
US5629316A (en) * | 1993-06-30 | 1997-05-13 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
US5672359A (en) * | 1993-07-21 | 1997-09-30 | The University Of Kentucky Research Foundation | Multicompartment hard capsule with control release properties |
US5827538A (en) * | 1993-07-22 | 1998-10-27 | Pfizer Inc. | Osmotic devices having vapor-permeable coatings |
US6074688A (en) * | 1995-06-06 | 2000-06-13 | Delsys Pharmaceautical Corporation | Method for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US5699649A (en) * | 1996-07-02 | 1997-12-23 | Abrams; Andrew L. | Metering and packaging device for dry powders |
US6197331B1 (en) * | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6350468B1 (en) * | 1997-12-17 | 2002-02-26 | Axcan Pharma Inc. | Double capsule for the administration of active principles in multiple therapies |
US5960609A (en) * | 1998-06-12 | 1999-10-05 | Microdose Technologies, Inc. | Metering and packaging method and device for pharmaceuticals and drugs |
US6428809B1 (en) * | 1999-08-18 | 2002-08-06 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
US20040224020A1 (en) * | 2002-12-18 | 2004-11-11 | Schoenhard Grant L. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
US20040185100A1 (en) * | 2003-03-03 | 2004-09-23 | Sprl Franpharma | Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin |
US20050053649A1 (en) * | 2003-09-08 | 2005-03-10 | Anne-Marie Chalmers | Medication delivery device |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040185119A1 (en) * | 2003-02-26 | 2004-09-23 | Theuer Richard C. | Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency |
US20090010997A1 (en) * | 2006-03-07 | 2009-01-08 | Orahealth Corporation | Multi-layer medical patch with impermeable center |
US8349120B2 (en) * | 2006-03-07 | 2013-01-08 | Ora Health Corporation | Multi-layer patch made on a sheet and enclosed in a blister |
US9248095B2 (en) | 2007-08-03 | 2016-02-02 | Shaklee Corporation | Nutritional supplement system |
US9763989B2 (en) | 2007-08-03 | 2017-09-19 | Shaklee Corporation | Nutritional supplement system |
US20100143533A1 (en) * | 2007-08-03 | 2010-06-10 | Shaklee Corporation | Nutritional supplement system |
US20090232886A1 (en) * | 2007-09-27 | 2009-09-17 | Sison Raymundo A | Oral dosage combination pharmaceutical packaging |
US20090087483A1 (en) * | 2007-09-27 | 2009-04-02 | Sison Raymundo A | Oral dosage combination pharmaceutical packaging |
US9132246B2 (en) | 2007-10-09 | 2015-09-15 | Microdose Therapeutx, Inc. | Inhalation device |
US8439033B2 (en) | 2007-10-09 | 2013-05-14 | Microdose Therapeutx, Inc. | Inhalation device |
US9539400B2 (en) | 2007-10-09 | 2017-01-10 | Microdose Therapeutx, Inc. | Inhalation device |
US8991390B2 (en) | 2010-01-05 | 2015-03-31 | Microdose Therapeutx, Inc. | Inhalation device and method |
US9974909B2 (en) | 2010-01-05 | 2018-05-22 | Microdose Therapeutx, Inc. | Inhalation device and method |
US10434267B2 (en) | 2010-01-05 | 2019-10-08 | Microdose Therapeutx, Inc. | Inhalation device and method |
Also Published As
Publication number | Publication date |
---|---|
JP2003517351A (en) | 2003-05-27 |
US6428809B1 (en) | 2002-08-06 |
CA2380596A1 (en) | 2001-02-22 |
AU6909800A (en) | 2001-03-13 |
US20020142035A1 (en) | 2002-10-03 |
DK1207809T3 (en) | 2009-07-20 |
US7404968B2 (en) | 2008-07-29 |
PT1207809E (en) | 2009-05-08 |
ES2323846T3 (en) | 2009-07-27 |
EP1207809B1 (en) | 2009-04-22 |
DE60042076D1 (en) | 2009-06-04 |
WO2001012103A1 (en) | 2001-02-22 |
ATE429190T1 (en) | 2009-05-15 |
EP1207809A4 (en) | 2005-11-30 |
EP1207809A1 (en) | 2002-05-29 |
US6702683B2 (en) | 2004-03-09 |
EP2052697A1 (en) | 2009-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7404968B2 (en) | Metering and packaging of controlled release medication | |
JP2005514966A (en) | Controlled release drug metering and packaging | |
Arora et al. | Pulsatile drug delivery systems: An approach for controlled drug delivery | |
AU703151B2 (en) | Multilayered controlled release pharmaceutical dosage form | |
AU601478B2 (en) | Administration and dosage form for drug active agents, reagents or the like and process for the preparation thereof | |
PL163843B1 (en) | Medical unit for administering active substances through the skin | |
AU2001263506A1 (en) | Encapsulating a toxic core within a non-toxic region in an oral dosage form | |
AU3289301A (en) | Multi-step drug dosage forms | |
JP2002509888A5 (en) | ||
US20040156903A1 (en) | Metering and packaging of controlled release medication | |
GB2353950A (en) | Capsules with two compartments | |
HRP20020124A2 (en) | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping | |
CZ420997A3 (en) | Layered tablet for controlled release of active compounds | |
Tumuluri | Pharmaceutical mini-tablets: a revived trend | |
KR20020038784A (en) | Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same | |
CN111757727A (en) | Method for producing a drug delivery system | |
AU770828B2 (en) | Metering and packaging of controlled release medication | |
Jadhav et al. | Pulsatile drug delivery system using core-in-cup approach: a review | |
AU2004200545B9 (en) | Metering and packaging of controlled release medication | |
Mathew et al. | Recent Technologies in Pulsatile Drug Delivery: A Review | |
Navneet et al. | Pulsatile drug delivery system an innovative approach for controlled drug delivery | |
US20060039977A1 (en) | Oral drug delivery system | |
Patel et al. | Current status of technologies and devices for chronotherapeutic drug delivery systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: MICRODOSE THERAPEUTX, INC., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:MICRODOSE TECHNOLOGIES, INC.;REEL/FRAME:022494/0764 Effective date: 20090220 Owner name: MICRODOSE THERAPEUTX, INC.,NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:MICRODOSE TECHNOLOGIES, INC.;REEL/FRAME:022494/0764 Effective date: 20090220 |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |